This video is featured in the 2024 ASH Annual Meeting Insights Hub

2024 ASH Annual Meeting Insights Hub
Avatar

ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available Therapy in JAK Inhibitor R/R MF

By 2024 ASH Annual Meeting Insights Hub FEATURING John Mascarenhas
By 2024 ASH Annual Meeting Insights Hub FEATURING John Mascarenhas
2 views
December 27, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

2024 ASH Annual Meeting Insights Hub: MDS & MPN Videos

05:46

New

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

28 views
04:51

New

ASH 2024 Summary: Survival Outcomes in Patients With MF & New or Wor…

2024 ASH Annual Meeting Insights Hub

A. Kuykendall

26 views
08:20

New

ASH 2024 Insights: Ven + HMA vs. HMA Alone in TP53m HR-MDS - Real-Wo…

2024 ASH Annual Meeting Insights Hub

T. Badar

21 views
View All

Related Videos

Total Health

West Oncology Conference

Sat, Feb 8, 2025
24:08

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

1.5K views
24:35

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

1.3K views
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

473 views
25:44

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

283 views
19:57

New

ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

128 views
07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
10:01

New

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

90 views
21:38

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

134 views
15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
20:15

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

164 views
20:54

New

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

102 views
16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
06:18

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

301 views
18:07

New

Selection of JAK1/2 Inhibitors for Primary Myelofibrosis

16th International Congress on Myeloproliferative Neoplasms

A. Gerds

78 views
35:48

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

163 views
17:23

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari

195 views
08:06

Current Management of Accelerated/Blast-Phase MPNs

UChicago Medicine

A. Patel

76 views
30:03

Experts Discuss Their Current Approach to Treating MF

MyCancerHaven

R. Vij, A. Yacoub

126 views
24:48

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal

333 views
AUTOPLAY